Skip to main content
. 2020 Dec 4;2020(1):570–578. doi: 10.1182/hematology.2020002547

Table 1.

Clinical trials evaluating alternative immune cells for CAR-based cancer therapy

National Clinical Trial identifier Clinical trial phase Cancer type Antigen target NK cell source Construct/method Dosage Status Location
Active CAR NK cell trials
NCT03056339 1/2 B-lymphoid malignancies, ALL, CLL, NHL CD19 Cord blood CAR.CD19-CD28-CD3ζ-iCasp9-IL15 3 dosage levels: Phase 1 portion completed, phase 2 recruiting MD Anderson Cancer Center, Houston, TX USA
105/kg
106/kg
107/kg
NCT00995137 1 B-ALL CD19 Haploidentical donor CAR.19-41BB-CD3ζ Unknown Completed St Jude Children’s Research Hospital, Memphis, TN
NCT04245722 1 B-cell lymphoma, CLL CD19 ± CD20 antibody (rituximab or obinutuzumab) Induced pluripotent stem cell–derived NK cells CAR.19-NKG2D-2B4-CD3ζ-IL15RF-hnCD16 Dose escalation, exact dosages unknown Recruiting University of Minnesota Masonic Cancer Center, Minneapolis, MN
NCT03940833 1/2 Multiple myeloma BCMA NK-92 cell line Unknown Unknown Recruiting China
NCT03415100 1 Solid tumors NKG2D ligands Autologous or allogeneic NK mRNA electroporation Unknown Recruiting China
NCT03940820 1/2 Solid tumors ROBO1 Unknown Unknown Recruiting China
NCT03941457 1/2 Pancreatic cancer ROBO1 Unknown Unknown Unknown Recruiting China
NCT03383978 1 Glioblastoma HER2 NK-92 CAR.HER2-CD28- CD3ζ 1 × 107-1 × 108 intracranial infusion Recruiting Germany
CAR-NK T cell trials
NCT03774654 1 Relapsed or refractory B-cell malignancies CD19 Allogeneic iNKT cells CAR.19-CD28- CD3ζ -IL15 4 dosage levels: Not yet recruiting Baylor Methodist–Texas Children’s, Houston, TX
1 × 107/m2
3 × 107/m2
1 × 108/m2
3 × 108/m2
NCT03294954 1 Relapsed or refractory neuroblastoma GD2 Autologous iNKT cells CAR.GD2-CD28-CD3ζ-IL15 4 dosage levels: Recruiting Baylor Methodist–Texas Children’s, Houston, TX
3 × 106/m2
1 × 107/m2
3 × 107/m2
1 × 108/m2
CAR γδ T cell trials
NCT02656147 1 B-cell leukemia and lymphoma CD19 Allogeneic Unknown Unknown Not yet recruiting China
γδ T cells
NCT04107142 1 Solid tumors NKG2D ligands Haploidentical or allogeneic γδ T cells Unknown 3 × 108- Not yet recruiting Malaysia
3 × 109 cells
CAR CIK trial
NCT03389035 1/2 Relapsed B-ALL CD19 Allogeneic (donor derived peripheral blood) CIK CAR.19-CD28-OX40- CD3ζ 4 dose levels: 1 × 106, 3 × 106 Recruiting Italy
Sleeping beauty transposon 7.5 × 106
15 × 106
CAR+ cells/kg

ALL, acute lymphoblastic leukemia; BCMA, B-cell maturation antigen; CLL, chronic lymphocytic leukemia; iCasp9, inducible caspase 9; mRNA, messenger RNA; NHL, non-Hodgkin lymphoma.